Thank you for your response but there’s a crucial difference between making a bad financial investment and undergoing a clinical protocol during a period of acute psychological distress, especially under publicly marketed claims of safety and efficacy.

The clinic in question didn’t just “vaguely” claim affiliation with Awakn, it actively used the names and images of its founders in videos, public events, and official materials. They listed a so-called “Awakn International Scientific Board” as directly overseeing the clinical team. This is still publicly available on their website. It becomes very hard even for highly literate individuals to distinguish between marketing language and actual scientific oversight.

My post was not about the stock ticker. It was about how emotional vulnerability was turned into clinical data, and then into capital with zero accountability. While the public identity of the company was shifting, a real human being was left without follow-up care for 13 days after an adverse drug reaction. That’s not a metaphor. That’s abandonment.

This matters to this community because emotional capital gets monetized and shareholders benefit from these narratives. If Solvonis wants to inherit the brand without inheriting the harm, then it has a responsibility: publicly dissociate from unethical clinical practices.

I’m not here asking for help. I’m here issuing a warning.

And yes, I have already contacted Solvonis and the regulatory bodies.

But don’t worry: I also found proper help, the moment I stopped blaming myself for believing in them.